Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

WuXi Healthcare Invests in US Genomics Testmaker 23andMe

publication date: Oct 21, 2015
WuXi Healthcare Ventures, the investment arm of WuXi PharmaTech, participated in the $115 million E financing of California's 23andMe. 23andMe offers a $199 direct-to-consumer saliva DNA test. According to one report, the test is a loss leader for the company, which is more interested in developing a genomics database than selling tests. About 80% of 23andMe's customers -- about 100 million people -- allow the company to include their DNA reports (anonymously) in a genomic database. As WuXi ramps up its genomics services, the DNA database have sparked its interest in 23andMe. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022